Simulations Plus (SLP) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
4 Feb, 2026Executive summary
Annual Meeting scheduled for February 12, 2026, will be held virtually to enhance accessibility for all shareholders.
Shareholders of record as of December 15, 2025, are eligible to vote on key proposals, including director elections and executive compensation matters.
Proxy materials are primarily distributed electronically to expedite access, conserve resources, and reduce costs.
Voting matters and shareholder proposals
Four directors are up for election to serve until the next annual meeting or until successors are qualified.
Proposal to ratify Rose, Snyder & Jacobs LLP as the independent auditor for the fiscal year ending August 31, 2026.
Amendment to the 2021 Equity Incentive Plan seeks to increase authorized shares from 2,500,000 to 3,450,000.
Advisory vote on the frequency of future say-on-pay votes for executive compensation, with options for every 1, 2, or 3 years.
Board recommends voting for all director nominees, the auditor ratification, the equity plan amendment, and a three-year frequency for say-on-pay votes.
Board of directors and corporate governance
Board has reviewed all proposals and recommends approval, citing alignment with shareholder and company interests.
Director nominees are Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia, and Sharlene Evans.
Latest events from Simulations Plus
- Integrated AI ecosystem and cross-selling drive future growth, with major upside in FY 2027.SLP
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - All proposals passed with strong support; no shareholder questions were raised.SLP
AGM 202612 Feb 2026 - Pro-ficiency integration and client budget trends drive growth outlook amid ongoing cost constraints.SLP
Stephens 26th Annual Investment Conference | NASH20243 Feb 2026 - $100M acquisition doubles market, expands platform, and boosts 2025 EPS outlook.SLP
M&A Announcement3 Feb 2026 - Q3 revenue up 14% to $18.5M; Pro-ficiency deal and dividend halt shift focus to growth.SLP
Q3 20243 Feb 2026 - Acquisition of Pro-ficiency doubles TAM and accelerates growth in biosimulation and clinical ops.SLP
KeyBanc Capital Markets Technology Leadership Forum2 Feb 2026 - AI, cloud, and validated science converge in a unified platform to accelerate drug development.SLP
Investor Day 202623 Jan 2026 - FY24 revenue up 18% to $70M; FY25 guidance targets up to $93M and higher margins.SLP
Q4 202419 Jan 2026 - 31% revenue growth led by software, but net income fell as integration costs rose.SLP
Q1 202510 Jan 2026